PRX-14040

PRX-14040 is a selective dopamine reuptake inhibitor developed by Prexa Pharmaceuticals. It exhibits 28-fold selectivity for the dopamine transporter over the norepinephrine transporter.

The molecule has been shown to reverse motivational deficits induced by the dopamine-depleting agent tetrabenazine in animal studies. PRX-14040 is part of the class of dopamine reuptake inhibitors and is categorized as an experimental drug with potential pro-motivational effects.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/PRX-14040
https://pubmed.ncbi.nlm.nih.gov/27296079/